Progenics Pharmaceuticals Inc. (PGNX)

[Dr_Thorfin]

On July 19, the Company Announced FDA Approval of RELISTOR® Tablets, Triggering a $50 Million Milestone Ultra-Orphan Radiotherapeutic Candidate AZEDRA® Registrational Trial Topline Results Expected Between December 2016 and March 2017Licensed PSMA Antibody Technology to Bayer and Recognition of $5 Million in Upfront and Milestone RevenuePhase 3 Study Enrollment of PSMA-Targeted SPECT/CT Imaging Agent 1404 OngoingSecond Quarter 2016 RELISTOR Subcutaneous (SC) Net Sales of $15.9 MillionOn Track to Initiate Phase 2/3 Trial for PyLTM Imaging Agent and Phase 1 Trial For 1095 This Year